Table 4 Responses in the three arms of the rituximab versus “watch-and-wait” study
Time of response evaluation | 7 months | 13 months | 25 months |
|---|---|---|---|
Arm A (W&W) | |||
+ CRu | 3 (2%) | 6 (3%) | 5 (4%) |
PR | 6 (3%) | 7 (4%) | 5 (4%) |
ORR | 9 (5%) | 13 (7%) | 10 (8%) |
Arm B (Rx4) | |||
CR + CRu | 35 (43%) | 36 (44%) | 30 (40%) |
PR | 25 (30%) | 22 (27%) | 10 (13%) |
ORR | 60 (73%) | 58 (71%) | 40 (53%) |
Arm C (Rx4RM) | |||
CR + CRu | 100 (54%) | 122 (67%) | 98 (70%) |
PR | 61 (33%) | 36 (20%) | 12 (9%) |
ORR | 161 (87%) | 158 (87%) | 110 (79%) |
p value (Arm B vs Arm C) | p = 0.0216 | p = 0.0077 | p < 0.0001 |